deucravacitinib vs TQH3906
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TYK2 · full Psoriasis pipeline
deucravacitinib · Sotyktu
Marketed by Bristol-Myers Squibb
NCT03611751 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo- and active-controlled trial of 1,020 participants. Both primary clinical endpoints at week 16 were met: deucravacitinib produced significantly more participants with sPGA 0/1 and PASI 75 responses than placebo.
Next expected readout: November 2026 · NCT05570955 (registry estimate)
Reported efficacy
The Percentage of Participants With sPGA Response of 0 or 1 (At week 16); The Percentage of Participants With PASI 75 Response (At week 16): The Percentage of Participants With sPGA Response of 0 or 1 (At week 16): Arm 1: BMS-986165 55.6% (95% CI 47.4 to 63.7) vs Arm 2: Placebo 6.8% (95% CI 1 to 12.5) (met)
Result source: NCT04167462
TQH3906
Developed by Sino Biopharmaceutical
NCT06542614 · Phase 2 · completed
This Phase 2 trial randomly assigned 209 people with plaque psoriasis to TQH3906 or placebo, with participants, carers, investigators and outcome assessors unaware of assignment. The primary measure was the proportion reaching PASI 75, a 75% improvement in psoriasis severity, at week 12. The sponsor reports more than 90% reaching PASI 75 and more than 70% reaching PASI 90 at the recommended dose, but gives no placebo figure and no statistical comparison, so the size of the advantage over placebo is not established by what has been released.
Next expected readout: September 2027 · NCT07724366 (registry estimate)
Reported efficacy
Proportion of patients achieving Psoriasis Area and Severity Index (PASI) 75 at week 12 (Up to week 12): At the recommended dose in the 209-patient study: PASI 75 above 90% and PASI 90 above 70% at 12 weeks (met)
Result source: NCT06542614
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | deucravacitinib | TQH3906 |
|---|---|---|
| PASI 75 | 53% vs 9.4%+43.6 vs placeboNCT036117519 other results
| —Trial running · NCT07724366 |
| PASI 90 | 27% vs 2.7%+24.3 vs placeboNCT036117512 other results
| —Trial running · NCT07724366 |
| PASI 100 | 10.2% vs 1.2%+9 vs placeboNCT036117512 other results
| —Trial running · NCT07724366 |
| sPGA 0/1 | 49.5% vs 8.6%+40.9 vs placeboNCT0361175111 other results
| —Trial running · NCT07724366 |
| DLQI, change | -10.2 vs -2.9−7.3 vs placeboNCT029318384 other results
| —Trial running · NCT07724366 |
PASI 75
- deucravacitinib
- 53% vs 9.4%+43.6 vs placeboNCT03611751
9 other results
- 58.4% vs 12.7% NCT03624127
- 68.8% vs 8.1% NCT04167462
- 53% vs 39.8% NCT03611751
- 58.4% vs 35.1% NCT03624127
- 75% vs 6.7% NCT02931838
- 66.7% vs 6.7% NCT02931838
- 9.1% vs 6.7% NCT02931838
- 38.6% vs 6.7% NCT02931838
- 68.9% vs 6.7% NCT02931838
- TQH3906
- —Trial running · NCT07724366
PASI 90
- deucravacitinib
- 27% vs 2.7%+24.3 vs placeboNCT03611751
2 other results
- 35.5% vs 4.2% NCT03624127
- 38.2% vs 1.4% NCT04167462
- TQH3906
- —Trial running · NCT07724366
PASI 100
- deucravacitinib
- 10.2% vs 1.2%+9 vs placeboNCT03611751
2 other results
- 14.2% vs 0.6% NCT03624127
- 4.2% vs 0% NCT04167462
- TQH3906
- —Trial running · NCT07724366
sPGA 0/1
- deucravacitinib
- 49.5% vs 8.6%+40.9 vs placeboNCT03611751
11 other results
- 53.6% vs 7.2% NCT03624127
- 55.6% vs 6.8% NCT04167462
- 49.5% vs 33.9% NCT03611751
- 53.6% vs 32.1% NCT03624127
- 75% vs 6.7% NCT02931838
- 64.4% vs 6.7% NCT02931838
- 20.5% vs 6.7% NCT02931838
- 38.6% vs 6.7% NCT02931838
- 75.6% vs 6.7% NCT02931838
- 35.5% vs 8.2% NCT05701995
- 51% vs 4.3% NCT05478499
- TQH3906
- —Trial running · NCT07724366
DLQI, change
- deucravacitinib
- -10.2 vs -2.9−7.3 vs placeboNCT02931838
4 other results
- -8.4 vs -2.9 NCT02931838
- -3.8 vs -2.9 NCT02931838
- -6.1 vs -2.9 NCT02931838
- -9.7 vs -2.9 NCT02931838
- TQH3906
- —Trial running · NCT07724366
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. deucravacitinib: 4 of 4 rows · TQH3906: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | deucravacitinib |
|---|---|
| Dropout rate | 0.2%BMS-986165a NCT03611751 · Phase 3 · monotherapy show 20 more results—BMS-986165 (Week 0 up to Week 16) NCT03611751 · Phase 3 · monotherapy —BMS-986165 (Week 0 up to Week 52) NCT03611751 · Phase 3 · monotherapy 0%BMS-986165 NCT03624127 · Phase 3 · monotherapy —BMS-986165 Week 0 up to Week 16 NCT03624127 · Phase 3 · monotherapy —BMS-986165 Week 0 up to Week 52 NCT03624127 · Phase 3 · monotherapy 9.6%Arm 1: BMS-986165 NCT04167462 · Phase 3 · monotherapy —BMS-986165 Week 0 up to Week 52 NCT04167462 · Phase 3 · monotherapy —BMS-986165 Week 16 up to Week 52 NCT04167462 · Phase 3 · monotherapy —Active Treatment - Deucravacitinib NCT05701995 · Phase 4 · registry result, not featured evidence 0.8%Deucravacitinib NCT05701995 · Phase 4 · registry result, not featured evidence —Placebo Controlled - Deucravacitin NCT05701995 · Phase 4 · registry result, not featured evidence —Active Treatment - Deucravacitinib NCT05478499 · Phase 4 · registry result, not featured evidence 8.7%Deucravacitinib NCT05478499 · Phase 4 · registry result, not featured evidence —Placebo Controlled - Deucravacitin NCT05478499 · Phase 4 · registry result, not featured evidence 8.1%6 mg QD NCT03924427 · Phase 3 · registry result, not featured evidence 4.5%12 mg QD NCT02931838 · Phase 2 · registry result, not featured evidence 13.3%6 mg BID NCT02931838 · Phase 2 · registry result, not featured evidence 6.7%3 mg BID NCT02931838 · Phase 2 · registry result, not featured evidence 18.2%3 mg QD NCT02931838 · Phase 2 · registry result, not featured evidence 22.7%3 mg QOD NCT02931838 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —BMS-986165a NCT03611751 · Phase 3 · monotherapy show 20 more results—BMS-986165 (Week 0 up to Week 16) NCT03611751 · Phase 3 · monotherapy —BMS-986165 (Week 0 up to Week 52) NCT03611751 · Phase 3 · monotherapy —BMS-986165 NCT03624127 · Phase 3 · monotherapy —BMS-986165 Week 0 up to Week 16 NCT03624127 · Phase 3 · monotherapy —BMS-986165 Week 0 up to Week 52 NCT03624127 · Phase 3 · monotherapy 2.7%Arm 1: BMS-986165 NCT04167462 · Phase 3 · monotherapy —BMS-986165 Week 0 up to Week 52 NCT04167462 · Phase 3 · monotherapy —BMS-986165 Week 16 up to Week 52 NCT04167462 · Phase 3 · monotherapy —Active Treatment - Deucravacitinib NCT05701995 · Phase 4 · registry result, not featured evidence —Deucravacitinib NCT05701995 · Phase 4 · registry result, not featured evidence —Placebo Controlled - Deucravacitin NCT05701995 · Phase 4 · registry result, not featured evidence —Active Treatment - Deucravacitinib NCT05478499 · Phase 4 · registry result, not featured evidence 3.9%Deucravacitinib NCT05478499 · Phase 4 · registry result, not featured evidence —Placebo Controlled - Deucravacitin NCT05478499 · Phase 4 · registry result, not featured evidence 5.4%6 mg QD NCT03924427 · Phase 3 · registry result, not featured evidence 2.3%12 mg QD NCT02931838 · Phase 2 · registry result, not featured evidence 6.7%6 mg BID NCT02931838 · Phase 2 · registry result, not featured evidence 2.2%3 mg BID NCT02931838 · Phase 2 · registry result, not featured evidence 4.5%3 mg QD NCT02931838 · Phase 2 · registry result, not featured evidence 2.3%3 mg QOD NCT02931838 · Phase 2 · registry result, not featured evidence |
| Serious AEs | —BMS-986165a NCT03611751 · Phase 3 · monotherapy show 20 more results1.6%BMS-986165 (Week 0 up to Week 16) NCT03611751 · Phase 3 · monotherapy 2.9%BMS-986165 (Week 0 up to Week 52) NCT03611751 · Phase 3 · monotherapy —BMS-986165 NCT03624127 · Phase 3 · monotherapy 2.1%BMS-986165 Week 0 up to Week 16 NCT03624127 · Phase 3 · monotherapy 5.8%BMS-986165 Week 0 up to Week 52 NCT03624127 · Phase 3 · monotherapy —Arm 1: BMS-986165 NCT04167462 · Phase 3 · monotherapy 2.7%BMS-986165 Week 0 up to Week 52 NCT04167462 · Phase 3 · monotherapy 0%BMS-986165 Week 16 up to Week 52 NCT04167462 · Phase 3 · monotherapy 4.9%Active Treatment - Deucravacitinib NCT05701995 · Phase 4 · registry result, not featured evidence —Deucravacitinib NCT05701995 · Phase 4 · registry result, not featured evidence 2.5%Placebo Controlled - Deucravacitin NCT05701995 · Phase 4 · registry result, not featured evidence 4.3%Active Treatment - Deucravacitinib NCT05478499 · Phase 4 · registry result, not featured evidence —Deucravacitinib NCT05478499 · Phase 4 · registry result, not featured evidence 1%Placebo Controlled - Deucravacitin NCT05478499 · Phase 4 · registry result, not featured evidence 6.8%6 mg QD NCT03924427 · Phase 3 · registry result, not featured evidence 0%12 mg QD NCT02931838 · Phase 2 · registry result, not featured evidence 0%6 mg BID NCT02931838 · Phase 2 · registry result, not featured evidence 2.2%3 mg BID NCT02931838 · Phase 2 · registry result, not featured evidence 2.3%3 mg QD NCT02931838 · Phase 2 · registry result, not featured evidence 2.3%3 mg QOD NCT02931838 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a nasopharyngitis 10.8% (placebo 11.4%) upper respiratory tract infection 4.9% (placebo 4.3%) diarrhoea 4.7% (placebo 7.5%) NCT03611751 · Phase 3 · monotherapy show 15 more resultsnasopharyngitis 16% (placebo 11.4%) upper respiratory tract infection 8.9% (placebo 4.3%) headache 5.4% (placebo 5.5%) NCT03611751 · Phase 3 · monotherapy nasopharyngitis 6.3% (placebo 4.2%) upper respiratory tract infection 6.3% (placebo 3.6%) headache 4.8% (placebo 3%) NCT03624127 · Phase 3 · monotherapy nasopharyngitis 18.1% (placebo 4.2%) upper respiratory tract infection 9.4% (placebo 3.6%) headache 6.6% (placebo 3%) NCT03624127 · Phase 3 · monotherapy upper respiratory tract infection 17.8% (placebo 18.9%) mouth ulceration 7.5% (placebo 5.4%) nasopharyngitis 6.8% (placebo 8.1%) NCT04167462 · Phase 3 · monotherapy psoriasis 11.8% (placebo 2.7%) headache 5.9% (placebo 0%) nasopharyngitis 5.9% (placebo 8.1%) NCT04167462 · Phase 3 · monotherapy covid-19 9.7% (placebo 4.1%) upper respiratory tract infection 7.8% (placebo 2%) nasopharyngitis 3.9% (placebo 4.1%) NCT05701995 · Phase 4 · registry result, not featured evidence acne 7.6% (placebo 4.1%) nasopharyngitis 6.7% (placebo 4.1%) covid-19 5.9% (placebo 4.1%) NCT05701995 · Phase 4 · registry result, not featured evidence nasopharyngitis 23.4% (placebo 17.8%) covid-19 12.8% (placebo 8.9%) upper respiratory tract infection 11.7% (placebo 6.7%) NCT05478499 · Phase 4 · registry result, not featured evidence nasopharyngitis 15.5% (placebo 17.8%) upper respiratory tract infection 11.7% (placebo 6.7%) acne 9.7% (placebo 2.2%) NCT05478499 · Phase 4 · registry result, not featured evidence 6 mg QD nasopharyngitis 31.1% acne 9.5% constipation 5.4% NCT03924427 · Phase 3 · registry result, not featured evidence 12 mg QD blood creatine phosphokinase increased 15.9% (placebo 2.2%) acne 9.1% (placebo 0%) diarrhoea 9.1% (placebo 4.4%) NCT02931838 · Phase 2 · registry result, not featured evidence 6 mg BID nasopharyngitis 15.6% (placebo 4.4%) blood creatine phosphokinase increased 8.9% (placebo 2.2%) upper respiratory tract infection 8.9% (placebo 2.2%) NCT02931838 · Phase 2 · registry result, not featured evidence 3 mg BID nasopharyngitis 11.1% (placebo 4.4%) aphthous ulcer 6.7% (placebo 0%) headache 6.7% (placebo 4.4%) NCT02931838 · Phase 2 · registry result, not featured evidence 3 mg QD nasopharyngitis 11.4% (placebo 4.4%) headache 9.1% (placebo 4.4%) psoriasis 6.8% (placebo 4.4%) NCT02931838 · Phase 2 · registry result, not featured evidence 3 mg QOD headache 9.1% (placebo 4.4%) nausea 9.1% (placebo 4.4%) blood immunoglobulin e increased 6.8% (placebo 2.2%) NCT02931838 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
deucravacitinib
show 15 more results
show 13 more results
show 5 more results
show 2 more results
show 2 more results
show 2 more results
show 1 more result
show 2 more results
show 2 more results
show 2 more results
show 1 more result
+ 11 further endpoints in the CSV export.
Psoriatic Arthritis
Shared mechanism: TYK2 · full Psoriatic Arthritis pipeline
deucravacitinib · Sotyktu
Marketed by Bristol-Myers Squibb
NCT04908202 · Phase 3 · active, not recruiting
This was a large (670-patient), randomized, quadruple-blinded, placebo-controlled trial with the primary endpoint being ACR20 response, a validated hard clinical measure of joint disease activity. The result was statistically significant and favored deucravacitinib (54.2% vs 34.1% on placebo, p<0.0001), meeting all criteria for the highest evidence tier.
Next expected readout: December 2027 · NCT07280702 (registry estimate)
Reported efficacy
Number of Participants Meeting American College of Rheumatology (ACR) 20 at Week 16: POETYK PsA-2 (NCT04908189), primary endpoint ACR20 at week 16: deucravacitinib 54.2% vs placebo 39.4%; p=0.0002 (met)
Result source: NCT04908189
TQH3906
Developed by Sino Biopharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2027 · NCT07406035 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Psoriatic Arthritis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | deucravacitinib | TQH3906 |
|---|---|---|
| ACR20 | 52.9% vs 31.8%+21.1 vs placeboNCT038810591 other result
| —Not reported |
| ACR50 | 24.3% vs 10.6%+13.7 vs placeboNCT038810591 other result
| —Not reported |
| PASI 75 | 42.4% vs 20.4%+22 vs placeboNCT038810591 other result
| —Not reported |
| Minimal disease activity | 22.9% vs 7.6%+15.3 vs placeboNCT038810591 other result
| —Not reported |
| HAQ-DI, change | -0.4 vs -0.1−0.3 vs placeboNCT038810591 other result
| —Not reported |
ACR20
- deucravacitinib
- 52.9% vs 31.8%+21.1 vs placeboNCT03881059
1 other result
- 62.7% vs 31.8% NCT03881059
- TQH3906
- —Not reported
ACR50
- deucravacitinib
- 24.3% vs 10.6%+13.7 vs placeboNCT03881059
1 other result
- 32.8% vs 10.6% NCT03881059
- TQH3906
- —Not reported
PASI 75
- deucravacitinib
- 42.4% vs 20.4%+22 vs placeboNCT03881059
1 other result
- 59.6% vs 20.4% NCT03881059
- TQH3906
- —Not reported
Minimal disease activity
- deucravacitinib
- 22.9% vs 7.6%+15.3 vs placeboNCT03881059
1 other result
- 23.9% vs 7.6% NCT03881059
- TQH3906
- —Not reported
HAQ-DI, change
- deucravacitinib
- -0.4 vs -0.1−0.3 vs placeboNCT03881059
1 other result
- -0.4 vs -0.1 NCT03881059
- TQH3906
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
TQH3906: no structured comparison results are available for Psoriatic Arthritis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. deucravacitinib: 4 of 4 rows · TQH3906: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | deucravacitinib |
|---|---|
| Dropout rate | 10%6 mga NCT03881059 · Phase 2 · registry result, not featured evidence show 7 more results—6 mg NCT03881059 · Phase 2 · registry result, not featured evidence —6 mg QD NCT03881059 · Phase 2 · registry result, not featured evidence —6 mg QD NCT03881059 · Phase 2 · registry result, not featured evidence 11.9%12 mg NCT03881059 · Phase 2 · registry result, not featured evidence —12 mg NCT03881059 · Phase 2 · registry result, not featured evidence —12 mg QD NCT03881059 · Phase 2 · registry result, not featured evidence —12 mg QD NCT03881059 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 4.3%6 mga NCT03881059 · Phase 2 · registry result, not featured evidence show 7 more results—6 mg NCT03881059 · Phase 2 · registry result, not featured evidence —6 mg QD NCT03881059 · Phase 2 · registry result, not featured evidence —6 mg QD NCT03881059 · Phase 2 · registry result, not featured evidence 6%12 mg NCT03881059 · Phase 2 · registry result, not featured evidence —12 mg NCT03881059 · Phase 2 · registry result, not featured evidence —12 mg QD NCT03881059 · Phase 2 · registry result, not featured evidence —12 mg QD NCT03881059 · Phase 2 · registry result, not featured evidence |
| Serious AEs | —6 mga NCT03881059 · Phase 2 · registry result, not featured evidence show 7 more results7.7%6 mg NCT03881059 · Phase 2 · registry result, not featured evidence 0%6 mg QD NCT03881059 · Phase 2 · registry result, not featured evidence 6.4%6 mg QD NCT03881059 · Phase 2 · registry result, not featured evidence —12 mg NCT03881059 · Phase 2 · registry result, not featured evidence 0%12 mg NCT03881059 · Phase 2 · registry result, not featured evidence 0%12 mg QD NCT03881059 · Phase 2 · registry result, not featured evidence 9.5%12 mg QD NCT03881059 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 6 mga aspartate aminotransferase increased 15.4% (placebo 0%) headache 15.4% (placebo 9.1%) hypertension 15.4% (placebo 0%) NCT03881059 · Phase 2 · registry result, not featured evidence show 5 more results6 mg QD bronchitis 10% (placebo 0%) diarrhoea 10% (placebo 0%) dizziness 10% (placebo 0%) NCT03881059 · Phase 2 · registry result, not featured evidence 6 mg QD headache 12.8% (placebo 9.1%) nasopharyngitis 12.8% (placebo 0%) bronchitis 6.4% (placebo 0%) NCT03881059 · Phase 2 · registry result, not featured evidence 12 mg pyrexia 18.8% (placebo 0%) alanine aminotransferase increased 12.5% (placebo 0%) aphthous ulcer 12.5% (placebo 0%) NCT03881059 · Phase 2 · registry result, not featured evidence 12 mg QD blood pressure increased 11.1% (placebo 0%) dizziness 11.1% (placebo 0%) furuncle 11.1% (placebo 0%) NCT03881059 · Phase 2 · registry result, not featured evidence 12 mg QD nasopharyngitis 26.2% (placebo 0%) covid-19 11.9% (placebo 0%) rash 9.5% (placebo 0%) NCT03881059 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
deucravacitinib
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 15 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: deucravacitinib's landscape · TQH3906's landscape